Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 323 of the 323 references it cites were found in a registry or an index.

Primary biliary cholangitis

Abstract

Primary biliary cholangitis is an autoimmune liver disease that predominantly affects women. It is characterised by a chronic and destructive, small bile duct, granulomatous lymphocytic cholangitis, with typical seroreactivity for antimitochondrial antibodies. Patients have variable risks of progressive ductopenia, cholestasis, and biliary fibrosis. Considerations for the cause of this disease emphasise an interaction of chronic immune damage with biliary epithelial cell responses and encompass complex, poorly understood genetic risks and environmental triggers. Licensed disease-modifying treatment focuses on amelioration of cholestasis, with weight-dosed oral ursodeoxycholic acid. For patients who do not respond sufficiently, or patients with ursodeoxycholic acid intolerance, conditionally licensed add-on therapy is with the FXR (NR1H4) agonist, obeticholic acid. Off-label therapy is recognised as an alternative, notably with the pan-PPAR agonist bezafibrate; clinical trial agents are also under development. Baseline characteristics, such as young age, male sex, and advanced disease, and serum markers of liver injury, particularly bilirubin and ALP, are used to stratify risk and assess treatment responsiveness. Parallel attention to the burden of patient symptoms is paramount, including pruritus and fatigue.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(20)31607-x

Cites

323 of 323 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 323 references

Cited by

See all 253

Metadata

Authors
Lleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M.
Affiliations
  • Peking University First Hospital (CN)
  • University of California, Davis (US)
  • University of Toronto (CA)
Corresponding author
Hirschfield, Gideon M
Venue
The Lancet
Publisher
Elsevier BV
Published
2020-12
Volume
396
Issue
10266
Pages
1915-1926
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2753306570
Cited by
253
References
323
Citations by year
2026: 28 · 2025: 48 · 2024: 58 · 2023: 46 · 2022: 46 · 2021: 22 · 2020: 1
FWCI
3.83
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institutes of Health (DK090019)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
Keywords
primary biliary cirrhosis, autoimmune liver disease, antimitochondrial antibodies, cholestasis, biliary fibrosis, ductopenia, ursodeoxycholic acid, obeticholic acid, FXR agonists, bezafibrate, PPAR agonists, disease-modifying therapy, risk stratification, pruritus, fatigue, sex differences
MeSH terms
Autoimmune Diseases, Chenodeoxycholic Acid, Cholagogues and Choleretics, Cholangitis, Fatigue, Humans, Pruritus, Risk Factors, Ursodeoxycholic Acid, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Primary biliary cholangitis. https://app.cochat.ai/papers/10.1016/s0140-6736(20)31607-x
The paper
Lleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M. (2020). Primary biliary cholangitis. The Lancet. https://doi.org/10.1016/s0140-6736(20)31607-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.